Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances
January 05, 2021 07:00 ET | Source: Ocuphire Pharma Ocuphire Pharma
Nyxol is in Late Stage Clinical Development for A New Ophthalmic Indication
Top Line Data from LYNX-1 Expected 3Q2021
FARMINGTON HILLS, Mich., Jan. 05, 2021 (GLOBE NEWSWIRE) Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced the initiation of patient recruitment and screening in late December for its LYNX-1 Phase 3 registration study evaluating the safety and efficacy of Nyxol
® in night vision disturbances (NVD) at multiple sites in the US.
1 of 19
Marvin W. Berkowitz of UMSL presented Epstein Hebrew Academy Academic Principal Itta Boyko and Judaic studies curriculum coordinator Shiffy Landa certificates marking the completion of the first year of the Character Education for Emerging Leaders program.
Photo: August Jennewein